It's a challenge to know how much it helps to add systemic therapy (e.g., chemotherapy) to a woman's regimen of breast cancer care. For a woman with a favorable prognosis, chemotherapy may add relatively little benefit - but put her through a great deal of difficulty. Genomic testing can help understand who may benefit from chemotherapy and how it impacts the risk of recurrence.
Aim 1: Examine patient and physician factors associated with the use of the 21-gene assay.
Aim 2: Examine patient and clinician factors associated with use of chemotherapy and the impact of the assay and its results on use.
Aim 3: Examine the impact of use of the assay on patient knowledge about risk and benefits of chemotherapy and satisfaction with the decision-making process.
Participants include 3200 patients with early stage invasive, estrogen receptor-positive breast cancer and their treating oncologist (approximately 270) in state-wide New Jersey and Georgia Surveillance, Epidemiology, and End Results (SEER) registries.